α-Glucosidase-IN-20
Modify Date: 2024-04-03 17:02:35
α-Glucosidase-IN-20 structure
|
Common Name | α-Glucosidase-IN-20 | ||
|---|---|---|---|---|
| CAS Number | 420809-56-9 | Molecular Weight | 359.48 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C23H21NOS | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of α-Glucosidase-IN-20α-Glucosidase-IN-20 (Compound 3B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.01 μM. α-Glucosidase-IN-20 shows anti-diabetic activity[1]. |
| Name | α-Glucosidase-IN-20 |
|---|
| Description | α-Glucosidase-IN-20 (Compound 3B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.01 μM. α-Glucosidase-IN-20 shows anti-diabetic activity[1]. |
|---|---|
| Related Catalog | |
| In Vivo | α-Glucosidase-IN-20 (Compound 3B; 10 and 20 mg/kg; p.o.; daily, for 4 weeks) has anti-diabetic activity in Streptozocin (HY-13753)-induced diabetic rats[1]. α-Glucosidase-IN-20 (10 and 20 mg/kg; p.o.; once) significantly decreases the serum glucose level after the administration of glucose (3 g/kg, oral) in rats[1]. α-Glucosidase-IN-20 (2000 mg/kg; p.o.; daily, for 2 weeks) demonstrates no mortality in mice[1]. Animal Model: Male Wistar albino rats (170-200 g), Streptozotocin-induced diabetes model[1] Dosage: 10 and 20 mg/kg Administration: Oral administration; daily, for 4 weeks Result: Decreased the level of blood glucose, reversed Streptozocin-induced body weight loss. Showed antihyperlipidemic effects on Streptozotocin-induced diabetes, reduced to a significant level of serum biomarkers. |
| References |
| Molecular Formula | C23H21NOS |
|---|---|
| Molecular Weight | 359.48 |